



HAL
open science

Genes encoding multiple forms of phospholipase A(2) are expressed in immature forms of human leukemic blasts.

Rémi Fiancette, Christelle Vincent-Fabert, M. Donnard, Dominique Bordessoule, P. Turlure, F. Trimoreau, Yves Denizot

► To cite this version:

Rémi Fiancette, Christelle Vincent-Fabert, M. Donnard, Dominique Bordessoule, P. Turlure, et al.. Genes encoding multiple forms of phospholipase A(2) are expressed in immature forms of human leukemic blasts.. *Leukemia*, 2009, epub ahead of print. 10.1038/leu.2009.36 . hal-00381287

HAL Id: hal-00381287

<https://hal.science/hal-00381287>

Submitted on 5 May 2009

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Genes encoding multiples forms of phospholipase A₂ are expressed in immature forms of human leukemic blasts

Letter to the Editor

Phospholipase A₂ (PLA₂) catalyzes the hydrolysis of the *sn*-2 position of membrane glycerophospholipids to liberate the eicosanoid precursor arachidonic acid (AA).^{1,2} Three distinct families have been documented: low molecular weight soluble forms of PLA₂ (sPLA₂); Ca²⁺-dependent high molecular weight PLA₂ (cPLA₂); and Ca²⁺-independent high molecular weight PLA₂ (iPLA₂). The sPLA₂ family is implicated in several biological processes such as inflammation and host defense.^{1,2} Nine isoenzymes have been identified. Among them sPLA₂-IB is the pancreatic one. sPLA₂-IIA is constitutively expressed in various organs related to immune response such as bone marrow spleen and thymus. sPLA₂-V is found in several immune cells such as macrophage, mast cells and type II helper T cells. sPLA₂-X is expressed in the digestive tract, immune organs and blood leukocytes. The cPLA₂ family consisted of four members, cPLA₂-IVA, cPLA₂-IVB, cPLA₂-IVC, cPLA₂-IVD; cPLA₂-IVA being the central regulator of stimulus-coupled cellular AA release.^{1,2} The iPLA₂ (PLA₂-VI) plays a major role in phospholipids remodeling.

Eicosanoid products of the cyclooxygenase (COX) and lipoxygenase (LOX) pathways of AA are important mediators of malignant proliferation.³ Deregulated PLA₂ activity contributes to the pathogenesis of several malignancies including prostate cancer, ovarian carcinoma and colorectal adenocarcinoma.^{1,2} The COX and LOX pathways of AA have been recently documented on immature leukemic blasts of patients with acute myeloid (AML) and acute lymphoid (ALL) leukaemia.^{4,5} Thus, freshly isolated AML and ALL blasts express COX-1, produce the AA metabolite prostaglandin E₂ (PGE₂), express

functional EP₂ receptors and increase their growth in response to exogenously added PGE₂. The World Health Organization (WHO) has proposed a classification system divides AML into several broad groups: AML with genetic abnormalities, AML with multilineage dysplasia, AML related to previous chemotherapy or radiation and AML not otherwise specified. The latter group contains a subgroup, AML without maturation, which consisted of the weaker immature blast group. In view of the potentially important oncogenic action of PLA₂ in leukemic proliferation, quantitative polymerase chain reaction (Q-PCR) was utilized to determine which of PLA₂ mRNAs were expressed in AML blasts without maturation and ALL blasts.

Blood samples recovered on EDTA were obtained from twenty one AML patients and ten B ALL patients at diagnosis according to the Helsinki recommendations. AML patients consisted in a homogeneous group of patients with blasts without signs of maturation and no genetic abnormality. Blood samples with more than 85% blast cells as circulating leukocytes were used. Leucocytosis ranged from 10 to 219 G/l. Immediately after recovery leukemic blasts were isolated by separation on a Ficoll gradient and washed one time with Hank's balanced salts solution (HBSS). The blast purity (>98%) was controlled by flow cytometry analysis. Blast viability (>95%) was judged by trypan blue exclusion. Blast RNA was immediately extracted with Tripure (Roche GmbH, Mannheim, Germany) and was stored at -80°C until used. As a control group, blood samples were recovered from 7 healthy volunteers. Control blood mononuclear cells were recovered and processed exactly as for leukemic blast samples.

In a first set of experiments we investigated if mRNAs derived from the four cPLA₂ genes were detected in AML and ALL leukemic blasts. As shown in Figure 1 (left part), mRNAs derived from three of the four cloned cPLA₂ genes are detected in human leukemic blasts. PLA₂-IVD transcripts were not present at detectable levels in AML and ALL

leukemic blasts and in blood mononuclear cells from healthy individuals (data not shown). In contrast, PLA₂-IVA, PLA₂-IVB and PLA₂-IVC were detected. Similar amounts of PLA₂-IVB and PLA₂-IVC transcripts were found in AML and ALL blasts and control cells. Both enzymes show little specificity for the *sn*-2 fatty acid.^{1,2} In contrast, PLA₂-IVA transcripts were markedly (p=0.006) reduced in ALL blasts as compared with blood mononuclear cells. PLA₂-IVA preferentially hydrolyses phospholipids containing AA at the *sn*-2 position. PLA₂-IVA is ubiquitously and constitutively expressed in most cells and tissues. One notable exception is mature B and T cells which do not contain detectable levels of PLA₂-IVA.¹ Q-PCR analysis reveals that PLA₂-IVA levels were also markedly lowered in immature forms of ALL blasts. The high levels of AA documented in ALL blasts have been previously related to an elevated Δ^6 desaturase activity.⁶ Low levels of PLA₂-IVA in ALL blasts might also explain these elevated AA amounts. PLA₂-VI (iPLA₂) transcript levels were higher (p=0.003) in AML and ALL leukemic blasts. PLA₂-VI was originally reported to mediate phospholipids remodelling and, thus, to act as a housekeeping protein without significant roles in cell growth.^{1,2} Several recent studies have demonstrated that PLA₂-VI exhibited roles in cell regulation, growth and death. Especially, one mechanism by which PLA₂-VI mediates cell growth involves regulation of AA release, P53 and MAPK activation.⁷ A role for PLA₂-VI may be suggested in the growth of AML and ALL blasts. The technique employed in this study allowed measurement of the absolute levels of any mRNA. So it was possible to evaluate the levels of each of the isoforms relative to one another. Results indicated the following rank of magnitude for cPLA₂ in leukemic blasts: PLA₂-VI > PLA₂-IVA = PLA₂-IVB > PLA₂-IVC. Together, these observations might suggest PLA₂-VI as a novel and interesting target for drug development for leukemic therapy. However, given the ubiquitous expression of PLA₂-VI and its role in glycerophospholipid metabolism, drug strategies targeting PLA₂-VI must exhibit selectivity

to avoid undesired side effects.

In another set of experiments we investigated if mRNAs derived from the nine sPLA₂ genes (*i.e.* PLA₂-IB, PLA₂-IIA, PLA₂-IID, PLA₂-IIE, PLA₂-IIF, PLA₂-III, PLA₂-V, PLA₂-X and PLA₂-XII) were detected in AML and ALL leukemic blasts. PLA₂-IIE and PLA₂-III were not present at detectable levels in AML and ALL leukemic blasts and control blood mononuclear cells (data not shown). In contrast transcripts for other sPLA₂ subtypes could be detected (Figure 1, right part). Results indicated the following rank of magnitude for sPLA₂ in leukemic blasts: PLA₂-IB > PLA₂-XII > PLA₂-X > PLA₂-IID > PLA₂-IIA = PLA₂-V > PLA₂-IIF. Levels of PLA₂-IB and PLA₂-X transcripts were higher (p=0.0001) in AML blasts than in control cells. In contrast PLA₂-IIA (p=0.0005), PLA₂-IID (p=0.0007) and PLA₂-V (p=0.0009) were markedly reduced while PLA₂-XII and PLA₂-IIF ones were unchanged. PLA₂-X transcripts were higher (p=0.0006) in ALL blasts than in control cells. In contrast PLA₂-IIA transcripts levels were reduced (p=0.001) while PLA₂-IB, PLA₂-IID, PLA₂-IIF, PLA₂-V and PLA₂-XII ones were unchanged. Such variations of PLA₂ subtypes would be of importance for leukemic patients. Thus, coagulation activation was often observed in patients with acute leukaemia. PLA₂-IIA, PLA₂-IID and PLA₂-V, which possess potent anticoagulant activity,¹ are markedly lowered in AML patients suggesting a putative link between PLA₂ activity and coagulation disorders. Bacterial and fungal infections are the major cause of morbidity and mortality in acute leukemic patients. A decreased PLA₂-IIA activity which has physiologically significant bactericidal activity,^{1,2} and a decreased PLA₂-V one that plays a role in innate immunity against fungal invasion^{1,2} might be implicated in these infections. Numerous evidences have highlighted that cytosolic PLA₂-IVA is the key enzyme for AA release from phospholipids of mammalian cells; AA being the first step for the biosynthesis of eicosanoids. Only those sPLA₂ species that have a high specific activity of phospholipids hydrolysis and that can bind well to

phosphatidylcholine-rich membranes, the PLA₂-V and PLA₂-X, have the capacity to release fatty acids when added to mammalian cells. As shown in Figure 1, the increase of PLA₂-X transcripts in leukemic blasts is higher than the decrease of their PLA₂-V transcripts. Thus, as lipolytic enzyme, PLA₂-X might contribute to the generation of lipid mediators. Of interest PGE₂, a COX metabolite of AA, was recently reported to stimulate the growth of leukemic blasts through an EP₂ receptor dependent pathway.⁴

These results demonstrate that mRNA from four out of five cytosolic PLA₂ (PLA₂-IVA, PLA₂-IVB, PLA₂-IVC and PLA₂-VI) and six out of nine sPLA₂ (PLA₂-IB, PLA₂-IIA, PLA₂-IID, PLA₂-V, PLA₂-X and PLA₂-XII) are present in leukemic blasts and that their mRNA transcript levels exhibited important variations as compared to blood mononuclear cells (summarized in Table I). One of the more notable findings is that leukemic blasts expressed high amounts of PLA₂-VI and PLA₂-X. This could be extremely significant as these two enzymatic activities play a major role in AA release for the generation of COX and LOX derived lipid mediators. In conclusion these results indicate that immature forms of leukemic AML and ALL blasts have the potential to express multiple isoforms of cPLA₂ and sPLA₂ which could be of importance given the potential role of these enzyme activities in inflammation, generation of lipidic mediators, anticoagulant activity and bacterial infection. Investigation of PLA₂ transcripts in other AML such as AML with genetic abnormalities and with multilineage dysplasia deserve now to be investigated.

References

1. Kudo I, Murakami M. Phospholipase A₂ enzymes. *Prostaglandins Other Lipid Mediat* 2002; **68-69**: 3-58.
2. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A₂. *Annu Rev Biochem* 2008; **77**: 495-520.
3. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. *Cancer Metastasis Rev* 2007; **26**: 525-534.
4. Truffinet V, Donnard M, Vincent C, Faucher JL, Bordessoule D, Turlure P, *et al.* Cyclooxygenase-1, but not -2, in blast cells of patients with acute leukemia. *Int J Cancer* 2007; **121**: 924-927.
5. Vincent C, Fiancette R, Donnard M, Bordessoule D, Turlure P, Trimoreau F, *et al.* 5-LOX, 12-LOX and 15-LOX in immature forms of human leukemic blasts. *Leuk Res* 2008; **32**: 1756-1762.
6. Gerhard A, Häfer R, Zintl F. Fatty acid composition of lymphocyte membrane phospholipids in children with acute leukaemia. *Cancer Lett* 2001; **173**: 139-144.
7. Hooks SB, Cummings BS. Role of Ca²⁺-independent phospholipase A₂ in cell growth and signalling. *Biochem Pharmacol* 2008; **76**: 1059-1067.

R Fiancette¹, C Vincent¹, M Donnard², D Bordessoule^{1,3}, P Turlure³, F Trimoreau², Y. Denizot¹

¹Université de Limoges, Centre National de la Recherche Scientifique, CNRS UMR 6101, France

²Laboratoire d'Hématologie, CHU Dupuytren, Limoges, France

³Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Dupuytren, Limoges, France.

Corresponding author details:

Y. Denizot, PhD, Université de Limoges, Centre National de la Recherche Scientifique, CNRS UMR 6101, Faculté de Médecine, 2 rue Dr. Marcland, 87025 Limoges, France.

Phone: (33) 5 55 43 58 96

Fax: (33) 5 55 43 58 97

e-mail: yves.denizot@unilim.fr

Acknowledgements: This work was supported in part by a grant from “Le Lions Club de la Corrèze, Zone 33 District 103 Sud”.

Legend to Figure 1

Q-PCR analysis of cytosolic PLA₂ and soluble PLA₂ transcripts in leukemic blasts.

Q-PCR was performed in duplicate by using TaqMan assay reagents according to the manufacturer's recommendations (Applied Biosystems, Foster City, CA) (product references - PLA₂-IB: Hs00386701-m1; PLA₂-IIA: Hs00179898-m1; PLA₂-IID: Hs00173860-m1; PLA₂-IIF: Hs00224482; PLA₂-IVA: Hs00233352-m1; PLA₂-IVB: Hs00979952-m1; PLA₂-IVC: Hs00234345-m1; PLA₂-IVD: Hs00603557-m1; PLA₂-V: Hs00173472-m1; PLA₂-VI: Hs001/85926-m1; PLA₂-X: Hs00358567-m1; PLA₂-XII: Hs00830106-s1). Gene expression levels were normalized to 18S RNA (product reference Hs99999901-s1). Amounts of various transcripts were compared to sample with the lowest level of transcripts (a patient who was arbitrary quoted 1). (●) indicates patients with no detectable transcript. Significance was assessed by using the Kruskal-Wallis test followed by a Mann-Whitney *U*-test. A Bonferroni adjustment indicated a $p < 0.016$ as significant.

Table 1

	Soluble PLA ₂									Cytosolic PLA ₂				
	IB	IIA	IID	IIE	IIF	III	V	X	XII	IVA	IVB	IVC	IVD	VI
Controls	Yes	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
ALL	↔	↓	↔	No	↔	No	↔	↑	↔	↓	↔	↔	No	↑
AML	↑	↓	↓	No	↔	No	↓	↑	↔	↔	↔	↔	No	↑

Comparison of soluble PLA₂ and cytosolic PLA₂ transcripts levels in ALL blasts, AML blasts and control blood mononuclear cells. “Yes” and “No” indicated the presence and the absence of transcripts, respectively. “↔,↑,↓” indicated similar, elevated and decreased levels of transcripts as compared to blood mononuclear cell, respectively.

